PURSUIT Risk Score Mortality Calculator

PURSUIT Risk Score Mortality Calculator Explanation and Clinical Context The PURSUIT risk score was derived from a large international randomized trial of patients with unstable angina and non ST elevation myocardial infarction who received standard care with or without the glycoprotein two b three a inhibitor eptifibatide. It combines five bedside clinical features age sex worst Canadian Cardiovascular Society angina class in the preceding six weeks clinical signs of heart failure and the presence of ST segment depression on the first electrocardiogram to estimate the thirty day risk of death and the combined outcome of death or myocardial infarction. Scoring assigns a larger weight to older age in particular to patients in the seventh and eighth decade and above while male sex severe angina recent history clinical heart failure and resting ischemic ST segment depression each add further points so that the total score reflects the overall burden of ischemia and hemodynamic compromise.

Observational work that applied this score outside the original trial has shown that higher PURSUIT values are associated with more extensive epicardial coronary disease lower left ventricular ejection fraction and higher short term and longer term mortality while lower values identify patients with relatively preserved ventricular function fewer vessel involvement and low early event rates. In contemporary practice the two thousand twenty five acute coronary syndromes guideline from the American Heart Association and partner societies emphasizes GRACE and TIMI scores as the preferred tools for routine risk stratification and for guiding decisions about invasive strategy but it also cites key studies that used PURSUIT and other legacy scores when discussing the broader evidence base for structured risk assessment in non ST elevation acute coronary syndromes. This calculator therefore serves as an adjunct to guideline endorsed tools by providing a simple bedside estimate of relative thirty day risk using only clinical history and electrocardiogram findings helping clinicians to recognize patients who may benefit from closer monitoring early coronary angiography and intensive secondary prevention while acknowledging that absolute event rates may be lower today than in the original PURSUIT trial because of advances in reperfusion therapy antithrombotic regimens and comprehensive guideline directed care.

Reference Boersma E Pieper K Steyerberg E and colleagues Predictors of outcome in patients with acute coronary syndromes without persistent ST segment elevation Results from an international trial of nine thousand four hundred sixty one patients Circulation two thousand one volume one hundred one pages two thousand five hundred fifty seven to two thousand five hundred sixty seven. Brilakis E Wright R Kopecky S and collaborators Association of the PURSUIT risk score with predischarge ejection fraction angiographic severity of coronary artery disease and mortality in a community population with non ST elevation acute myocardial infarction American Heart Journal two thousand three volume one hundred forty six pages eight hundred eleven to eight hundred eighteen. Rao S and the writing committee two thousand twenty five ACC AHA ACEP NAEMSP SCAI Guideline for the management of patients with acute coronary syndromes Journal of the American College of Cardiology volume eighty five pages two thousand one hundred thirty five to two thousand two hundred thirty seven.